Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2014

01-06-2014 | Letter to the Editor

Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis

Authors: Bunyamin Kisacik, Muhammet Said Dag, Yavuz Pehlivan, Kenan Ugurlu, Ozge Kaya Mercan, Musa Aydinli, Seda Duygulu Devay, Mehmet Sayarlioglu, Ahmet Mesut Onat

Published in: Rheumatology International | Issue 6/2014

Login to get access

Abstract

Anti-cyclic citrullinated peptide (anti-CCP) was positive in 11.5 % and rheumatoid factor was positive in 8.8 % of the patients with Brucella. After a comparative evaluation, we have found out that there was not a statistical significance concerning the anti-CCP levels between the patients with brucellosis and healthy control.
Literature
1.
Colmenero JD, Reguera JM, Martos F, Sanchez-de-Mora D, Delgado M, Causse M, Martin-Farfanm A, Juarez C (1996) Complications associated with brucellosis melitensis infection: a study of 530 cases. Medicine 75:195–211PubMedCrossRef
2.
Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O, Akdeniz H (2010) Clinical manifestations and complications in 1,028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis. Jun; 14(6):e469–78. Epub 2009 Nov 11. Review
3.
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146(11):797–808PubMedCrossRef
4.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
Metadata
Title
Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis
Authors
Bunyamin Kisacik
Muhammet Said Dag
Yavuz Pehlivan
Kenan Ugurlu
Ozge Kaya Mercan
Musa Aydinli
Seda Duygulu Devay
Mehmet Sayarlioglu
Ahmet Mesut Onat
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2777-1

Other articles of this Issue 6/2014

Rheumatology International 6/2014 Go to the issue

Original Article

Are there differences in quality of life, symptomatology and functional capacity among different obesity classes in women with fibromyalgia? The al-Ándalus project

Original Article

A meta-analysis of the relationship between aspartic acid (D)-repeat polymorphisms in asporin and osteoarthritis susceptibility

Letter to the Editor

IL-32, a potential therapeutic target for rheumatoid arthritis?

Original Article

Candidate’s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis

Letter to the Editor

Evaluation of mean platelet volume in familial Mediterranean fever; insight from the methodological aspect

Original Article

Clinical management of patients with hip and knee osteoarthritis: patient satisfaction with treatment switch
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits